Patents by Inventor John C. Alverdy
John C. Alverdy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230285446Abstract: The disclosure provides products and methods of treating diseases and disorders involving microbial pathogens, such as intestinal microbial pathogens, e.g., Pseudomonas aeruginosa, by administering an effective amount of a phosphorylated polyethylene glycol compound of defined structural organization. Those diseases and disorders characterized by an epithelium attacked by a microbial pathogen are contemplated, including gastrointestinal infections and inflammation, e.g., treatment of intestinal or esophageal anastomosis or treatment or suppression of anastomotic leakage.Type: ApplicationFiled: January 18, 2023Publication date: September 14, 2023Applicants: The University of Chicago, UChicago Argonne, LLCInventors: John C. Alverdy, Matthew Tirrell, Olga Y. Zaborina, Jun Mao, Wei Chen
-
Patent number: 11571443Abstract: The disclosure provides products and methods of treating diseases and disorders involving microbial pathogens, such as intestinal microbial pathogens, e.g., Pseudomonas aeruginosa, by administering an effective amount of a phosphorylated polyethylene glycol compound of defined structural organization. Those diseases and disorders characterized by an epithelium attacked by a microbial pathogen are contemplated, including gastrointestinal infections and inflammation, e.g., treatment of intestinal or esophageal anastomosis or treatment or suppression of anastomotic leakage.Type: GrantFiled: September 29, 2017Date of Patent: February 7, 2023Assignee: The University of ChicagoInventors: John C. Alverdy, Matthew Tirrell, Olga Y. Zaborina, Jun Mao, Wei Chen
-
Publication number: 20210252040Abstract: Disclosed herein is the de novo synthesis of phosphorylated polyethylene glycol compounds with three defined ABA (hydrophilic/-phobic/-philic) structures: ABA-PEG10k-Pi10, ABA-PEG16k-Pi14, and ABA-PEG20k-Pi20 and linear polymer PEG20k-Pi20 absent of hydrophobic block. The disclosure also provides materials and methods for treating or reducing the risk or likelihood of developing, anastomotic leak or other microbe-mediated disorders by administering a therapeutically effective amount of a plasminogen inhibitor such as tranexamic acid and/or a phosphate-loaded polymer.Type: ApplicationFiled: April 23, 2019Publication date: August 19, 2021Applicants: THE UNIVERSITY OF CHICAGO, RUSH UNIVERSITY MEDICAL CENTERInventors: John C. ALVERDY, Olga Y. ZABORINA, Richard A. JACOBSON
-
Publication number: 20200016097Abstract: The present invention provides methods of protecting irradiated eukaryotic cells such as irradiated mammalian epithelial cells, from the deleterious effect of microbial pathogens such as Pseudomonas aeruginosa. The invention also provides methods of protecting irradiated organisms from such deleterious effects, resulting in reduced mortality and morbidity. Further provided are kits containing relatively high molecular weight biocompatible polymers such as polyethylene glycol, optionally supplemented with a protective polymer such as dextran and/or essential pathogen nutrients such as L-glutamine, along with instructions for administration to organisms to be exposed to radiation.Type: ApplicationFiled: October 24, 2018Publication date: January 16, 2020Inventors: John C. Alverdy, Olga Zaborina
-
Publication number: 20190247423Abstract: The disclosure provides products and methods of treating diseases and disorders involving microbial pathogens, such as intestinal microbial pathogens, e.g., Pseudomonas aeruginosa, by administering an effective amount of a phosphorylated polyethylene glycol compound of defined structural organization. Those diseases and disorders characterized by an epithelium attacked by a microbial pathogen are contemplated, including gastrointestinal infections and inflammation, e.g., treatment of intestinal or esophageal anastomosis or treatment or suppression of anastomotic leakage.Type: ApplicationFiled: September 29, 2017Publication date: August 15, 2019Inventors: John C. Alverdy, Matthew Tirrell, Olga Y. Zaborina, Jun Mao, Wei Chen
-
Publication number: 20180110639Abstract: A medical system for the treatment of morbid obesity comprising an inflatable balloon implanted in a gastric cavity, a percutaneous fillant delivery tube and a control module connected to the tube for regulating the inflation and deflation of the balloon. The balloon may be individually contoured and inflated to occupy a large volume of the gastric cavity to provide a feeling of satiety. The balloon may also be deflated to give the gastric cavity lining a rest during less critical time.Type: ApplicationFiled: June 5, 2017Publication date: April 26, 2018Inventor: John C. Alverdy
-
Patent number: 9937199Abstract: Materials and methods for preventing and treating anastomotic leaks are disclosed. Data establishes that pathogenic microbes interfere with establishing epithelial cell barriers in anastomoses and, more generally, with the reconnection of any two portions of like or different tissues comprising epithelia. Suitable prophylactic and therapeutic composition comprise, e.g., a phosphorylated high molecular weight polyethylene glycol compound.Type: GrantFiled: March 14, 2013Date of Patent: April 10, 2018Assignee: THE UNIVERSITY OF CHICAGOInventor: John C. Alverdy
-
Publication number: 20170281668Abstract: The present invention provides pharmaceutical compositions in the form of relatively high molecular weight biocompatible polymers such as polyethylene glycol, optionally supplemented with a protective polymer such as dextran and/or essential pathogen nutrients such as L-glutamine. Also provided are methods for preventing or treating gut-derived sepsis attributable to intestinal pathogens such as Pseudomonas aeruginosa by administering high molecular weight polyethylene glycol as well as methods for monitoring the administration of high molecular weight polyethylene glycol, such as in methods of preventing, ameliorating or treating microbe-induced epithelial disorders, as exemplified by gut-derived sepsis. Frequently, gut-derived sepsis arises as a complication in mammals recovering from surgical intervention or suffering from a disease or disorder, providing indications of suitable animals to receive preventative treatment.Type: ApplicationFiled: December 13, 2016Publication date: October 5, 2017Inventor: John C. Alverdy
-
Patent number: 9668900Abstract: A medical system for the treatment of morbid obesity comprising an inflatable balloon implanted in a gastric cavity, a percutaneous fillant delivery tube and a control module connected to the tube for regulating the inflation and deflation of the balloon. The balloon may be individually contoured and inflated to occupy a large volume of the gastric cavity to provide a feeling of satiety. The balloon may also be deflated to give the gastric cavity lining a rest during less critical time.Type: GrantFiled: May 23, 2014Date of Patent: June 6, 2017Assignee: ReShape Medical, Inc.Inventor: John C. Alverdy
-
Patent number: 9549946Abstract: The present invention provides pharmaceutical compositions in the form of relatively high molecular weight biocompatible polymers such as polyethylene glycol, optionally supplemented with a protective polymer such as dextran and/or essential pathogen nutrients such as L-glutamine. Also provided are methods for preventing or treating gut-derived sepsis attributable to intestinal pathogens such as Pseudomonas aeruginosa by administering high molecular weight polyethylene glycol as well as methods for monitoring the administration of high molecular weight polyethylene glycol, such as in methods of preventing, ameliorating or treating microbe-induced epithelial disorders, as exemplified by gut-derived sepsis. Frequently, gut-derived sepsis arises as a complication in mammals recovering from surgical intervention or suffering from a disease or disorder, providing indications of suitable animals to receive preventative treatment.Type: GrantFiled: November 9, 2015Date of Patent: January 24, 2017Assignee: THE UNIVERSITY OF CHICAGOInventor: John C. Alverdy
-
Publication number: 20160129038Abstract: The present invention provides pharmaceutical compositions in the form of relatively high molecular weight biocompatible polymers such as polyethylene glycol, optionally supplemented with a protective polymer such as dextran and/or essential pathogen nutrients such as L-glutamine. Also provided are methods for preventing or treating gut-derived sepsis attributable to intestinal pathogens such as Pseudomonas aeruginosa by administering high molecular weight polyethylene glycol as well as methods for monitoring the administration of high molecular weight polyethylene glycol, such as in methods of preventing, ameliorating or treating microbe-induced epithelial disorders, as exemplified by gut-derived sepsis. Frequently, gut-derived sepsis arises as a complication in mammals recovering from surgical intervention or suffering from a disease or disorder, providing indications of suitable animals to receive preventative treatment.Type: ApplicationFiled: November 9, 2015Publication date: May 12, 2016Inventor: John C. Alverdy
-
Publication number: 20150297634Abstract: Materials and methods for preventing and treating anastomotic leaks are disclosed. Data establishes that pathogenic microbes interfere with establishing epithelial cell barriers in anastomoses and, more generally, with the reconnection of any two portions of like or different tissues comprising epithelia. Suitable prophylactic and therapeutic composition comprise, e.g., a phosphorylated high molecular weight polyethylene glycol compound.Type: ApplicationFiled: March 14, 2013Publication date: October 22, 2015Applicant: The University of ChicagoInventor: John C. Alverdy
-
Patent number: 8845672Abstract: A medical system for the treatment of morbid obesity comprising an inflatable balloon implanted in a gastric cavity, a percutaneous fillant delivery tube and a control module connected to the tube for regulating the inflation and deflation of the balloon. The balloon may be individually contoured and inflated to occupy a large volume of the gastric cavity to provide a feeling of satiety. The balloon may also be deflated to give the gastric cavity lining a rest during less critical time.Type: GrantFiled: November 24, 2009Date of Patent: September 30, 2014Assignee: ReShape Medical, Inc.Inventor: John C. Alverdy
-
Publication number: 20140257358Abstract: A medical system for the treatment of morbid obesity comprising an inflatable balloon implanted in a gastric cavity, a percutaneous fillant delivery tube and a control module connected to the tube for regulating the inflation and deflation of the balloon. The balloon may be individually contoured and inflated to occupy a large volume of the gastric cavity to provide a feeling of satiety. The balloon may also be deflated to give the gastric cavity lining a rest during less critical time.Type: ApplicationFiled: May 23, 2014Publication date: September 11, 2014Applicant: Reshape Medical, Inc.Inventor: John C. Alverdy
-
Publication number: 20140142133Abstract: The invention provides prophylactic and therapeutic methods for administering a ?-opioid receptor antagonist, e.g., N-methylnaltrexone or a salt thereof, to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders, e.g., sepsis. Methods of reducing at least a symptom of sepsis and the risk of developing sepsis are also provided.Type: ApplicationFiled: October 23, 2013Publication date: May 22, 2014Applicant: The University of ChicagoInventors: John C. Alverdy, Jonathan Moss, Mark W. Lingen, Patrick A. Singleton, Joe G.N. Garcia
-
Publication number: 20120316190Abstract: The invention provides prophylactic and therapeutic methods for administering a ?-opioid receptor antagonist, e.g., N-methylnaltrexone or a salt thereof, to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders, e.g., inflammatory bowel disease. Methods of reducing the symptoms of inflammatory bowel disease and the risk of developing inflammatory bowel disease are also provided.Type: ApplicationFiled: May 30, 2012Publication date: December 13, 2012Applicant: THE UNIVERSITY OF CHICAGOInventors: John C. Alverdy, Jonathan Moss, Mark W. Lingen, Patrick A. Singleton, Joe G.N. Garcia
-
Publication number: 20120078017Abstract: The present invention provides methods of protecting irradiated eukaryotic cells such as irradiated mammalian epithelial cells, from the deleterious effect of microbial pathogens such as Pseudomonas aeruginosa. The invention also provides methods of protecting irradiated organisms from such deleterious effects, resulting in reduced mortality and morbidity. Further provided are kits containing relatively high molecular weight biocompatible polymers such as polyethylene glycol, optionally supplemented with a protective polymer such as dextran and/or essential pathogen nutrients such as L-glutamine, along with instructions for administration to organisms to be exposed to radiation.Type: ApplicationFiled: March 23, 2010Publication date: March 29, 2012Inventors: John C. Alverdy, Olga Zaborina
-
Publication number: 20100130998Abstract: A medical system for the treatment of morbid obesity comprising an inflatable balloon implanted in a gastric cavity, a percutaneous fillant delivery tube and a control module connected to the tube for regulating the inflation and deflation of the balloon. The balloon may be individually contoured and inflated to occupy a large volume of the gastric cavity to provide a feeling of satiety. The balloon may also be deflated to give the gastric cavity lining a rest during less critical time.Type: ApplicationFiled: November 24, 2009Publication date: May 27, 2010Inventor: John C. Alverdy
-
Publication number: 20090186949Abstract: The invention provides methods of screening for modulators of microbial PA-I lectin/adhesin activity, including modulators of PA-I expression, as well as the modulators so identified, pharmaceutical compositions and kits containing such modulators. These modulators include soluble and membrane-bound bacterial signaling compounds produced by cells of a host containing a microbial pathogen. Methods for preventing and treating cell disorders, such as epithelial cell disorders including gut-derived sepsis, a burn injury, neonatal necrotizing enterocolitis, severe neutropenia, toxic colitis, inflammatory bowel disease, enteropathy, transplant rejection, pouchitis, pig belly, Pseudomonas-mediated opthalmologic infection, Pseudomonas-mediated otologic infection and Pseudomonas-mediated cutaneous infection, using the modulators are contemplated, as are methods for ameliorating a symptom associated with such a disorder.Type: ApplicationFiled: February 28, 2007Publication date: July 23, 2009Applicant: THE UNIVERSITY OF CHICAGOInventors: John C. Alverdy, Joe G.N. Garcia, Steven Dudek
-
Publication number: 20090048624Abstract: A medical system (100) for the treatment of morbid obesity comprising an inflatable balloon (110) implanted in a gastric cavity, a percutaneous fillant delivery tube (120) and a control module (130) connected to the tube for regulating the inflation and deflation of the balloon. The balloon may be individually contoured and inflated to occupy a large volume of the gastric cavity to provide a feeling of satiety. The balloon may also be deflated to give the gastric cavity lining a rest during less critical time.Type: ApplicationFiled: October 24, 2008Publication date: February 19, 2009Inventor: John C. Alverdy